Genomic Health, Inc. (GHDX) Position Maintained by State Farm Mutual Automobile Insurance Co.

Genomic Health, Inc. (GHDX) Position Maintained by State Farm Mutual Automobile Insurance Co.

Other large investors have also bought and sold shares of the company. Pacad Investment Ltd. acquired a new stake in Genomic Health during the fourth quarter worth approximately $118,000. Dubuque Bank & Trust Co. acquired a new stake in Genomic Health during the first quarter worth approximately $142,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Genomic Health during the first quarter worth approximately $218,000. Stonebridge Capital Management Inc. acquired a new stake in Genomic Health during the first quarter worth approximately $259,000. Finally, Wetherby Asset Management Inc. increased its stake in Genomic Health by 4.4% in the fourth quarter. Wetherby Asset Management Inc. now owns 8,255 shares of the medical research company’s stock worth $243,000 after buying an additional 345 shares in the last quarter. Institutional investors own 89.50% of the company’s stock.

State Farm Mutual Automobile Insurance Co. maintained its stake in Genomic Health, Inc. (NASDAQ:GHDX) during the first quarter, Holdings Channel reports. The institutional investor owned 317,240 shares of the medical research company’s stock at the end of the first quarter. State Farm Mutual Automobile Insurance Co.’s holdings in Genomic Health were worth $9,990,000 at the end of the most recent quarter.

Genomic Health, Inc. (NASDAQ GHDX) traded up 5.23% during midday trading on Tuesday, hitting $32.21. The company had a trading volume of 261,032 shares. The stock has a 50 day moving average of $31.27 and a 200 day moving average of $30.45. Genomic Health, Inc. has a 52-week low of $24.81 and a 52-week high of $33.96. The firm’s market cap is $1.11 billion.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, May 9th. The medical research company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. The firm had revenue of $84 million during the quarter, compared to analysts’ expectations of $86.21 million. Genomic Health had a negative return on equity of 14.13% and a negative net margin of 5.77%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the business posted ($0.19) earnings per share. On average, analysts anticipate that Genomic Health, Inc. will post $0.02 EPS for the current year.

A number of equities research analysts have commented on the company. TheStreet upgraded Genomic Health from a “d+” rating to a “c-” rating in a research report on Monday, February 27th. Zacks Investment Research upgraded Genomic Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 16th. Jefferies Group LLC lifted their target price on Genomic Health from $29.00 to $33.00 and gave the company a “hold” rating in a research report on Wednesday, May 10th. Finally, Raymond James Financial, Inc. restated a “market perform” rating on shares of Genomic Health in a research report on Wednesday, May 3rd. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $32.00.

In related news, insider Steven Shak sold 5,000 shares of the stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $29.40, for a total value of $147,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Laura Leber sold 3,072 shares of the stock in a transaction on Monday, March 20th. The stock was sold at an average price of $31.88, for a total value of $97,935.36. The disclosure for this sale can be found here. Insiders sold a total of 66,072 shares of company stock worth $2,019,170 over the last ninety days. Corporate insiders own 47.00% of the company’s stock.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GHDX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Related posts

Leave a Comment